86
Participants
Start Date
April 5, 2006
Primary Completion Date
June 20, 2007
Study Completion Date
March 13, 2008
Pre-transfection F17
Dengue tetravalent Vaccine F17 Pre transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
Post-transfection F17
Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
Post-transfection F19
Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
Placebo
Sterile solution of buffered water (0.9% NaCl), U.S. FDA accepted vaccine excipient, phenol red dye(phenolsulfonphthalein, used in vaccines as a pH indicator); 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
Walter Reed Army Institute of Research, Silver Spring
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Walter Reed Army Institute of Research (WRAIR)
FED
U.S. Army Medical Research and Development Command
FED